Navigation Links
CVS Caremark Reports Record Second Quarter Results
Date:8/6/2013

d $4.4 billion of retail co-payments for the six months ended June 30, 2013 and 2012, respectively.(2)

Intersegment eliminations relate to two types of transaction: (i) Intersegment revenues that occur when Pharmacy Services Segment customers use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment customers, through the Company's intersegment activities (such as the Maintenance Choice program), elect to pick-up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $1.1 billion and $840 million for the three months ended June 30, 2013 and 2012, respectively, and $2.0 billion and $1.6 billion for the six months ended June 30, 2013 and 2012, respectively; gross profit and operating profit of $127 million and $97 million for the three months ended June 30, 2013 and 2012, respectively, and $265 million and $172 million for the six months ended June 30, 2013 and 2012, respectively. Supplemental Information(Unaudited) Pharmacy Services SegmentThe following table summarizes the Pharmacy Services Segment's performance for the respective periods:Three Months EndedJune 30,Six Months EndedJune 30,In millions2013201220132012Net revenues$

18,800$

18,423$

37,111$

36,722Gross profit9637771,7311,393Gross profit % of net revenues5.1

%4.2

%4.7

%3.8

%Operating expenses288266557533Operating expense % of ne
'/>"/>

SOURCE CVS Caremark Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
2. CVS Caremark Reports Record First Quarter Results
3. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
4. CVS Caremark Research Identifies Positive Link Between Medication Adherence and Employee Productivity
5. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
6. CVS Caremark To Present At Goldman Sachs 2012 Global Retailing Conference
7. CVS Caremark to Present at Morgan Stanley Global Healthcare Conference
8. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
9. CVS Caremark Donates More Than $100,000 to Hurricane Sandy Relief Efforts
10. CVS Caremark To Present At Lazard Capital Markets 9th Annual Healthcare Conference
11. CVS Caremark Reports Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... from its Phase I/II clinical trial of  VAL-083 ... the most common and deadly form of human ...
(Date:6/1/2015)... , June 1, 2015 CEFALY ... electrical nerve stimulation device specifically authorized for use prior ... data from a new PET trial showing that the ... in the brain in migraine patients, namely the orbitofrontal ... Tomography (PET) scan, which is an imaging test of the brain, used ...
(Date:6/1/2015)... June 1, 2015  Boston Biomedical, an industry leader ... cancer stem cell (CSC) pathways, will present clinical data ... multiple tumor types at the 2015 American Society of ... . Data presented at ASCO highlight ... that targets STAT3, leading to inhibition of the critical ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... recognize Linda with this important honor,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... Cornett, DSL, LSSBB (C), First Sergeant A Co., 15BSB ... of the Year Circle. She is recognized with this ... the nation's leading networking organization exclusively for professional women, ... Local Chapters. , “I'm pleased to recognize Sergeant Cornett ...
(Date:6/1/2015)... Ticket Down announces that the Golden State Warriors ... and now will face the Cleveland Cavaliers in the ... Oracle Arena in Oakland and the Quicken Loans Arena in ... season, the Golden State Warriors were the elite team that ... from their playoff failures from the year and riding the ...
(Date:6/1/2015)... CO (PRWEB) June 01, 2015 Atagi ... they have been named an Ultherapy® Ultra ... Plastic Surgery and Skin Aesthetics is one of only ... as a premier treatment provider. , Atagi Plastic ... in the Denver area has led the practice to ...
(Date:6/1/2015)... 2015 Rio Salado College’s Dental Clinic ... young adults this summer. , The clinics take place Friday, ... 3 p.m. at the Rio Salado Dental Clinic. The clinic ... “A big goal for us is to offer services to ... students,” said Nikki Shipp, Clinical Coordinator for Rio’s dental hygiene. ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 2Health News:Warriors NBA Finals Tickets: 2015 NBA Finals Feature the Golden State Warriors vs. the Cleveland Cavaliers 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Kids Receive Complimentary Dental Services at Rio Salado Dental Clinic 2
... Dental Laser Market, SAN CLEMENTE, Calif., Feb. ... Inc. (Nasdaq: BLTI ) announced the,formation of ... laser,division, Lasers4Dentistry, and a laser therapy division,Technology4Therapy. Jeffrey ... and Keith G. Bateman, Biolase,s former Executive Vice ...
... Va., Feb. 21 Federal Health Information,Technology (IT) spending ... $4.5,billion in 2013 at a compound annual growth rate ... IT market, according to a new report by,INPUT, the ... robust, several things remain in the way of even,more ...
... and Water Reuse are Honored, NEW ... curricular solution for pharmacy education, has been,awarded ... Electronic Publication or,Product from the Professional/Scholarly Publishing ... In addition, the McGraw-Hill,reference, Water Reuse: Issues, ...
... release is available in Spanish . , ... Country, Maria Luisa de Francisco Maiz provided a clinical-forensic evaluation ... that influence the length of legal time periods. , Brain ... only for their high incidence but also because they mainly ...
... There are numerous antidepressant medications currently on ... the debilitating symptoms of depression even with treatment. ... 15th issue of Biological Psychiatry set out to ... serotonin and norepinephrine reuptake inhibitors (SNRIs), like venlafaxine ...
... . , Ikerlan-IK4 (CIC microGUNE Microfluidics Unit - ... device that enables the verification of the optimum conditions for ... a microelectrode that measures the impedance and temperature of the ... be monitored from the moment of its extraction, during its ...
Cached Medicine News:Health News:Former Biolase CEO & EVP Launch Technology4Medicine 2Health News:Federal Health IT Market to Reach $4.5 Billion by 2013 2Health News:McGraw-Hill Professional Products Win Awards From Association of American Publishers 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 2Health News:Guidelines for evaluation of psychological side-effects of brain injury 3Health News:Comparison of venlafaxine and SSRIs in the treatment of depression 2Health News:A device that measures optimum state of an organ prior to transplanting has been patented 2
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... is a latex-free unisex system that ... catheterization designed to reduce the risk ... includes a 100% latex-free Mentor Self-Cath ... tab makes it easy to use, ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: